Two months ago, Novartis acknowledged its staff in Japan hid safety reports concerning patients in a clinical study of leukemia medicines. The evidence had been shredded or online files were deleted. At the time, the drug maker did not specify the actual number of cases, although some Japanese media reported the initial findings involved about 30 instances.
Now, though, Novartis says that at least 10,000 cases were uncovered and may never have been reported – and that the cover-up was actually in connection with 10 different medicines. These include the two leukemia treatments – Gleevec and Tasigna – as well as the Xolair asthma drug; the Exelon patch for Alzheimer’s and Parkinson’s diseases, and the Neoral medicine used to mitigate organ rejection.
I am just reasoning - according to modern paradigm Gleevec is a first targeted drug and shouldn't have any side-effects at all! Something is not correct here!
No comments:
Post a Comment